

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

**ELECTION OF VICE CHAIRMAN OF THE BOARD  
AND  
CHANGE OF GENERAL MANAGER AND CHIEF EXECUTIVE OFFICER**

**ELECTION OF VICE CHAIRMAN OF THE BOARD**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Junshi Biosciences Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Li Ning (“**Dr. Li**”) has been elected as the vice chairman of the third session of the Board with effect from the date of this announcement to the conclusion of the term of the third session of the Board. Dr. Li shall also serve as the chairman of the board of directors of TopAlliance Biosciences Inc., being a wholly-owned subsidiary of the Company, and shall be responsible for the overseas business of the Company.

Dr. Li’s biographical details are set out as follows:

Dr. Li Ning (李寧), aged 62, has been an executive Director since June 2018. From January 2018 to January 2024, he has served as the chief executive officer and general manager of the Company. Since December 2023, he has served as the director of TA BIOSCIENCES PTE. LTD., being a wholly-owned subsidiary of the Company. Dr. Li’s main experience prior to joining the Group includes: he held various positions, including team leader of the Office of Biostatistics, team leader of mathematical statistician and a statistical reviewer at the U.S. Food and Drug Administration; he was employed by Sanofi from September 2009 to January 2018, and the last position he held was Vice President Asia Regulatory Affairs in Global Regulatory Affairs; from November 2010 to November 2012, he was a guest professor at the Clinical Research Institute of Peking University and from January 2012 to December 2014, he was a part-time professor at the Medical Informatics Center of Peking University. Dr. Li obtained his bachelor’s degree in public health from Shanghai Medical College of Fudan University, the PRC in July 1984 and his master’s degree in medicine from Shanghai Medical College of Fudan University, the PRC in October 1987. He obtained his Ph.D. degree in preventive medicine from University of Iowa, the United States in August 1994.

As at the date of this announcement, Dr. Li is interested in 956,000 A Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”).

Save as disclosed above, Dr. Li has confirmed that he: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did he hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of SFO.

The Company has entered into a service contract with Dr. Li in relation to his appointment as an executive Director for a term commencing from 29 June 2021 and expiring on the conclusion of the term of the third session of the Board. The term of office is determinable by either party serving on the other not less than three months’ written notice, and subject to retirement by rotation and re-appointment in accordance with the articles of association of the Company (the “**Articles of Association**”) and the Listing Rules. Other than that, he has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Listing Rules requiring the prior approval of shareholders of the Company (the “**Shareholders**”) at general meetings, with the Company. Dr. Li’s annual emolument remains unchanged for his new role.

Save as disclosed above, there are no other matters concerning Dr. Li’s appointment as vice chairman of the Board that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

## **CHANGE OF GENERAL MANAGER AND CHIEF EXECUTIVE OFFICER**

### **Cessation of Dr. Li as general manager and chief executive officer**

Following the election of Dr. Li as vice chairman of the Board, Dr. Li will cease to be the general manager and chief executive officer of the Company. Dr. Li has confirmed that he has no disagreement with the Board, and there are no other matters that should be brought to the attention of the Shareholders in relation thereto.

### **Appointment of Dr. Zou Jianjun (“Dr. Zou”) as general manager and chief executive officer**

The role of general manager and chief executive officer of the Company will be assumed by Dr. Zou as approved by the Board with effect from the date of this announcement to the conclusion of the term of the third session of the Board. She shall be responsible for the overall work of the Company.

Dr. Zou’s biographical details are set out as follows:

Dr. Zou Jianjun (鄒建軍), aged 52, has been an executive Director since June 2022. From April 2022 to January 2024, she served as the deputy general manager and global research and development president of the Company. From August 1995 to September 2005, she served as the resident and attending physician at the department of oncology under the department of clinical medicine at the 301 Hospital of the People’s Liberation Army\* (解放軍301醫院) and at the department of oncology at the Shanghai Changzheng Hospital\* (上海長征醫院) respectively. From October 2005 to October 2012, she served as the medical manager of the research and development

department and the head of the oncology therapeutic team of Bayer China, and the head of global medical affairs at the United States headquarters of Bayer Pharmaceuticals in New Jersey. From October 2012 to September 2015, she served as the head of China Medical Affairs at Celgene Pharmaceuticals in the United States. From September 2015 to April 2022, she served as the chief medical officer and deputy general manager at Jiangsu Hengrui Pharmaceutical Co., Ltd.\* (江蘇恒瑞醫藥股份有限公司). Dr. Zou enrolled into the department of clinical medicine at the Fourth Military Medical University\* (第四軍醫大學) in 1989 and graduated with a bachelor's degree in clinical medicine in 1995. She graduated with a doctorate degree in clinical oncology from the Second Military Medical University\* (第二軍醫大學) in August 2005.

Save as disclosed above, Dr. Zou has confirmed that she: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did she hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of SFO.

The Company has entered into a service contract with Dr. Zou in relation to her appointment as an executive Director for a term commencing from 29 June 2022 and expiring on the conclusion of the term of the third session of the Board. The term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Listing Rules. Other than that, she has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company. Dr. Zou's annual emolument remains unchanged for her new role.

Save as disclosed above, there are no other matters concerning Dr. Zou's appointment as general manager and chief executive officer of the Company that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome Dr. Li and Dr. Zou taking up the new positions.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 12 January 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun and Dr. Wang Gang as executive Directors; Dr. Feng Hui, Mr. Tang Yi and Dr. Li Xin as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.*

\* For identification purpose only